By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Orexigen Therapeutics, Inc. 

48 Wall Street
Suite 1100
New York  New York  10005  U.S.A.
Phone: 212-918-4650 Fax: 212-918-4801


SEARCH JOBS


Industry
Biotechnology






Company News
Orexigen (OREX) To Provide Business Update And Discuss Fourth Quarter And Year End 2016 Financial Results On March 28, 2017 3/8/2017 11:32:59 AM
Orexigen (OREX) Release: Company Announces Spanish Launch Of Mysimba (Naltrexone Hcl / Bupropion Hcl Prolonged Release) In Partnership With Laboratorios Farmace┬┤Uticos Rovi, S.A. 1/25/2017 8:27:59 AM
Orexigen (OREX) Announces Publication Of Contrave (Naltrexone Hcl And Bupropion Hcl Extended-Release Tablets) Real-World Study Results In "Obesity" 1/6/2017 7:03:27 AM
Orexigen (OREX) Highlights Key Business Priorities For 2017 1/5/2017 9:59:13 AM
Orexigen (OREX) Announces Commercialization And Distributorship Agreement With Biologix FZCO For Contrave (Naltrexone Hcl / Bupropion Hcl Prolonged Release) For Ten Countries In The Middle East 12/19/2016 8:02:21 AM
Orexigen (OREX) Announces Commercialization And Distributorship Agreement With Consilient Health Ltd. For Mysimba (Naltrexone Hcl / Bupropion Hcl Prolonged Release) In The UK And Ireland 12/8/2016 7:24:03 AM
Orexigen (OREX) Announces Commercialization And Distributorship Agreement With Valeant (VRX) For Contrave (Naltrexone HCL / Bupropion HCL Extended Release) In Australia And New Zealand 11/9/2016 11:38:28 AM
Orexigen (OREX) Reports Business And Financial Results For The Third Quarter Ended September 30, 2016 11/4/2016 6:46:59 AM
Orexigen (OREX) To Provide Business Update And Discuss Third Quarter 2016 Financial Results On November 3, 2016 10/21/2016 7:49:51 AM
Orexigen (OREX) To Speak At The Rodman & Renshaw 18th Annual Global Investment Conference 9/8/2016 10:05:34 AM
12345678910...
//-->